Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IVD National Fee Schedule, MDUFMA Oversight Among AdvaMed 2003 Goals

This article was originally published in The Gray Sheet

Executive Summary

Securing adequate Medicare payment for in vitro diagnostics is one of several legislative priorities for AdvaMed in 2003

You may also be interested in...

Congress To OMB: Adequate Funds Needed For User Fee Program In FY 2004

Congressional health panel chairmen are strongly urging White House Office of Management & Budget Director Mitch Daniels to set aside $15 mil. for medical device user fees in the administration's FY 2004 budget request

User Fee Submission Process To Be Explained In Upcoming FR Notice

FDA will likely publish a Federal Register notice after the Nov. 5 elections detailing the steps companies must take to submit device user fees, the agency says

FDA Extra FY 2003 Funding, User Fee Program Launch A Given – Industry

FDA will receive the additional $15 mil. in funding that it needs in FY 2003 to implement the just-passed device user fee legislation, the medical device industry expects

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts